Whether PPARγ agonists sensitize NSCLCs to chemotherapy and are of therapeutic benefit, or whether other Hif-1α-dependent signaling pathways might interfere in this tumor type, could be relatively easily answered from researchers’ long clinical experience with the use of PPARγ agonists. This evidence concerns the gene HIF1A and neoplasm.